肥胖对肋骨骨折手术稳定化结局的影响
本研究基于创伤质量改进项目数据库(2017-2022年),纳入18岁及以上、多发肋骨骨折和/或连枷胸并接受手术稳定化(SSRF)的钝性创伤患者18,952例,其中肥胖7,176例(38%)。肥胖组与非肥胖组的中位损伤严重度评分均为17,肥胖组肺损伤发生率更低(89.5% vs 92.4%,p<0.001)。肥胖组总体呼吸系统并发症发生率更高(13.7% vs 11.3%,p<0.001),包括急性呼吸窘迫综合征(2.2% vs 1.6%)、非计划再插管(8.0% vs 7.1%)和肺栓塞(2.1% vs 1.4%);两组死亡率相似(2.8% vs 2.4%,p=0.173)。多因素分析显示,肥胖与呼吸系统并发症风险升高相关(OR 1.29;95%CI 1.17-1.42;p<0.001),死亡率风险两组相似(OR 1.17;95%CI 0.96-1.42;p=0.13)。
要点
- 接受SSRF的钝性创伤肋骨骨折患者中38%为肥胖;肥胖组总体呼吸系统并发症13.7% vs 非肥胖组11.3%(p<0.001)。
- 多因素分析:肥胖与呼吸系统并发症风险升高独立相关(OR 1.29;95%CI 1.17-1.42;p<0.001)。
- 肥胖组与非肥胖组死亡率相似(2.8% vs 2.4%,p=0.173;校正OR 1.17;95%CI 0.96-1.42;p=0.13),未达统计学显著。
- 两组中位损伤严重度评分均为17,但肥胖组肺损伤发生率更低(89.5% vs 92.4%,p<0.001)。
- 肥胖组急性呼吸窘迫综合征2.2% vs 1.6%、非计划再插管8.0% vs 7.1%、肺栓塞2.1% vs 1.4%(均p<0.05)。
适用人群与场景
- 创伤质量改进项目数据库(2017-2022年)中18岁及以上、多发肋骨骨折和/或连枷胸并接受手术稳定化(SSRF)的钝性创伤患者,共18,952例,其中肥胖7,176例(38%)。
研究设计与关键结果
- 研究类型:基于创伤质量改进项目数据库(2017-2022年)的分析;样本量18,952例接受SSRF的钝性创伤肋骨骨折患者,肥胖7,176例(38%)。
- 主要终点:肥胖组总体呼吸系统并发症(非计划再插管、急性呼吸窘迫综合征、呼吸机相关性肺炎)发生率13.7% vs 非肥胖组11.3%(p<0.001)。
- 多因素分析:肥胖与呼吸系统并发症风险升高相关(OR 1.29;95%CI 1.17-1.42;p<0.001)。
- 次要终点:肥胖组急性呼吸窘迫综合征2.2% vs 1.6%、非计划再插管8.0% vs 7.1%、肺栓塞2.1% vs 1.4%(均p<0.05);两组中位损伤严重度评分均为17,肥胖组肺损伤发生率更低(89.5% vs 92.4%,p<0.001)。
- 死亡率:肥胖组2.8% vs 非肥胖组2.4%(p=0.173),校正后OR 1.17(95%CI 0.96-1.42;p=0.13),两组相似。
证据类型、等级与局限
- 证据类型:基于创伤质量改进项目数据库的分析;证据等级:治疗/照护管理,Level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对接受SSRF的肥胖钝性创伤肋骨骨折患者,作者认为脂肪组织可能提供一定外部保护,但与术后呼吸系统并发症增加独立相关;作者认为需进一步研究以制定减少该人群并发症、促进康复的策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Blunt trauma patients (BTPs) frequently present with rib fractures. Surgical stabilization of rib fractures (SSRF) has shown to improve outcomes by reducing complications. Given the increasing prevalence of obesity, understanding its influence on surgical outcomes after SSRF is warranted.
OBJECTIVE: We aimed to evaluate the impact of obesity on SSRF outcomes in BTPs with rib fractures, hypothesizing that obese patients would have an increased associated risk of respiratory complications.
METHODS: Trauma Quality Improvement Program database (2017-2022) was queried for BTPs 18 years or older with multiple rib fractures and/or flail segment undergoing SSRF. Obese ((+)obese) patients were compared with nonobese ((-)obese) patients. The primary outcome was respiratory complications (unplanned reintubation, acute respiratory distress syndrome, and ventilator-associated pneumonia). Bivariate and multivariable analyses were performed.
RESULTS: From 18,952 BTPs with rib fractures who underwent SSRF, 7,176 (38%) were obese. Both groups had similar median Injury Severity Scores of 17; however, the (+)obese group had lower rates of lung injuries (89.5% vs. 92.4%, p < 0.001). (+)Obese patients had higher rates of overall respiratory complications (13.7% vs. 11.3%, p < 0.001), including acute respiratory distress syndrome (2.2% vs. 1.6%), unplanned reintubation (8.0% vs. 7.1%), and pulmonary embolism (2.1% vs. 1.4%) (all p < 0.05); however, both (+)obese and (-)obese cohorts had similar rates of mortality (2.8% vs. 2.4%, p = 0.173). On multivariable analysis, (+)obese patients had an increased associated risk of respiratory complications (odds ratio, 1.29; 95% confidence interval, 1.17-1.42; p < 0.001), but risk of mortality remained similar between cohorts (odds ratio, 1.17; 95% confidence interval, 0.96-1.42; p = 0.13).
CONCLUSION: In this study, 38% of patients undergoing SSRF were obese. Despite similar Injury Severity Scores, obese patients had lower rates of lung injuries but had an increased associated risk of respiratory complications. Adipose tissue may provide some external protection but is independently associated with increased postoperative respiratory challenges. Further research is needed to develop strategies that reduce complications and enhance recovery in this population.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
参考来源
- Aryan N, Grigorian A, Nahmias J, et al. Impact of obesity on outcomes of surgical stabilization of rib fractures. J Trauma Acute Care Surg. 2025. PMID: 41198081. doi:10.1097/TA.0000000000004788
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。